Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin.
about
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozymeThe X-ray structure of the complex formed in the reaction between oxaliplatin and lysozymeAccelerated Hantzsch electrospray synthesis with temporal control of reaction intermediatesDetermination of the binding sites for oxaliplatin on insulin using mass spectrometry-based approaches.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSPalladium(II) and platinum(II) bind strongly to an engineered blue copper protein.Sensitive Marker of the Cisplatin-DNA Interaction: X-Ray Photoelectron Spectroscopy of CL.The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cellsProteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.Isotopic analyses by ICP-MS in clinical samples.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding.Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs.Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry.The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro.Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability.Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP).Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin.Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.A mass spectrometric and molecular modelling study of cisplatin binding to transferrin.Fluorescent sensing of monofunctional platinum species.Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.Sequence-dependent attack on peptides by photoactivated platinum anticancer complexes.Efficiently Detecting Metallodrug-Protein Adducts: Ion Trap versus Time-of-Flight Mass AnalyzersMass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI
P2860
Q27643373-4445C9B7-4204-49CD-A0E5-7B04AAEABB6DQ27690763-DCF22DD6-9045-4854-BC5A-02547FAEA351Q33836013-9E9AF76A-EF9F-40C9-9961-6416C3AFDB0AQ33965008-52F14BE0-A67C-4BB9-A4CA-DBAE55EA15ABQ34394993-443D8C8F-21A4-4615-97B2-A0C30A62C5E7Q35553261-0815E6AC-6067-4CFE-87EC-74285E303F8DQ36362182-A487881F-F3DD-45E4-92D0-D8D8EE37D0DAQ37055940-A8967153-1792-4461-BC59-C9AD067878A8Q37576021-19EF17A8-8191-4A0B-8A09-EC8917944BE2Q37808951-447298C0-6B51-4ED8-AA1E-8893069F49EBQ38052005-A5F6CA8C-AB88-460E-93E3-612922BBD22EQ38052406-F8B6BE6E-6B96-4883-AD22-A0B835B62939Q38105454-6CC38DB7-C8E9-4086-8213-5537C30E51F7Q38796925-A68E60BC-23D2-41B7-8B5F-767EC71F03ADQ39788547-A3DA45CC-FEC5-438F-96A4-90966EC3608EQ39995024-28AB5C47-DC9D-413B-8D63-4FB5CB7C92D8Q43529077-24C2C8FF-2D71-4110-A1A9-FA575419C7C3Q43537472-184A530B-7029-4101-BDBF-49623D235C0EQ43729194-39F884E4-A2E9-4AAA-A5E3-15C966F97003Q44473824-E77D35BA-F08E-4142-A939-1B0407DF1328Q44963722-C74E08D2-B414-48FA-847F-757A53766587Q45795847-6EE8EBA5-169D-4836-AF36-8AF070779AD3Q46729293-8EE1CF09-943B-48C2-9E8F-65ECE739A100Q46761280-ECDD143B-21ED-42C6-B51B-922B67637955Q46834044-8D86C0F8-F469-4CB4-BE3A-994BF1CFEFE0Q55322316-25D54D82-B7F5-4F9A-83F7-B5B511F35727Q57693530-62C68E03-8F2B-46F7-863E-29B4B112FFB1Q58858960-09A42E90-BF5E-4ECE-AD44-B44AB71B4717
P2860
Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Determination of drug binding ...... of cisplatin with transferrin.
@en
Determination of drug binding ...... of cisplatin with transferrin.
@nl
type
label
Determination of drug binding ...... of cisplatin with transferrin.
@en
Determination of drug binding ...... of cisplatin with transferrin.
@nl
prefLabel
Determination of drug binding ...... of cisplatin with transferrin.
@en
Determination of drug binding ...... of cisplatin with transferrin.
@nl
P2093
P2860
P356
P1476
Determination of drug binding ...... of cisplatin with transferrin.
@en
P2093
Claire S Allardyce
Jonathan Coffey
Neil Johnson
P2860
P304
P356
10.1002/RCM.662
P577
2002-01-01T00:00:00Z